Functional Gastrointestinal Disorders and Quality of Life

Functional gastrointestinal disorders (FGIDs) encompass a spectrum of chronic conditions—including irritable bowel syndrome and functional dyspepsia—characterised by persistent or recurrent digestive symptoms without identifiable structural abnormalities. These disorders are now understood as disorders of gut–brain interaction, in which bidirectional communication between the enteric nervous system and central nervous system modulates motility, visceral sensitivity and mucosal immunity. Symptoms such as abdominal pain, bloating and altered bowel habits impose a substantial burden on patients’ daily activities, mental health and social functioning. The prevalence of FGIDs varies by region and diagnostic criteria but may exceed 40 per cent in some populations. Quality of life is assessed using disease-specific scales (for example the IBS Severity Scoring System) and generic health questionnaires, revealing impairments in physical functioning, emotional well-being and work productivity. Management relies on a personalised biopsychosocial approach, combining dietary modification, pharmacotherapy, psychological therapies and, increasingly, modulation of the gut microbiota to relieve symptoms and restore life quality.

Research from Nature Portfolio

Recent clinical research has demonstrated that targeted probiotic supplementation can yield sustained symptomatic relief in functional dyspepsia. In an eight-week randomised trial, high-dose Bifidobacterium animalis subsp. lactis BL-99 significantly improved dyspeptic symptom scores compared with placebo and standard acid-suppressing therapy. Metagenomic and metabolomic analyses indicated that BL-99 enriched short-chain fatty acid–producing taxa, elevated colonic and systemic levels of acetate and butyrate, and increased serum gastrin, suggesting mechanisms by which microbiota modulation confers durable benefit.

Seminal microbiome investigations have further elucidated the link between microbial composition and symptom severity in irritable bowel syndrome. Large-scale 16S rRNA sequencing revealed that patients with diarrhoeal and mixed subtypes exhibit reduced diversity of butyrate-producing Clostridiales and diminished methanogen populations, correlating with heightened abdominal pain, bloating and impaired mucosal barrier function. These insights underscore the potential of microbial signatures both as biomarkers of disease activity and as targets for personalised interventions aimed at improving quality of life.

Functional Gastrointestinal Disorders and Quality of Life publication trend

The graph below shows the total number of articles in functional gastrointestinal disorders and quality of life across all publications each year (not limited to Nature Index journals).

Technical terms

Gut–brain axis: The complex, bidirectional signalling network linking the central nervous system and the enteric nervous system, modulating gastrointestinal function and behaviour.

Functional dyspepsia: A form of FGID characterised by bothersome post-prandial fullness, early satiation or epigastric pain in the absence of structural disease.

Irritable bowel syndrome (IBS): A chronic FGID defined by recurrent abdominal pain associated with altered bowel habits, subtyped by predominant stool pattern.

Short-chain fatty acids (SCFAs): Metabolites such as acetate, propionate and butyrate produced by microbial fermentation of dietary fibres, with roles in mucosal health and immune modulation.

Microbiota: The community of microorganisms—including bacteria, archaea and fungi—residing in the gastrointestinal tract, influencing digestion, immunity and neuromodulation.

Quality of life: A multidimensional construct reflecting an individual’s physical, mental and social well-being, often assessed by validated patient-reported outcome measures.

References

1. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet (2023).
2. Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial. Nature Communications (2024).
3. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology (2020).
4. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Scientific Reports (2015).